Dexcom (DXCM) Q2 2026 earnings review
Massive Margin Expansion Overshadows Modest Revenue Growth
Dexcom delivered a powerful Q2 marked by a profitability inflection. While top-line revenue grew a stable 13% to $1.31 billion, the real story played out on the bottom line. Non-GAAP operating margin surged 590 basis points year-over-year to 25.1%, completely reversing the gross margin and operational efficiency concerns that plagued the company in 2025. Strategically, the positive readout from the CONNECT trial derisks Dexcom's largest future growth catalyst: Medicare coverage for Type 2 non-insulin patients. Management confidently raised full-year guidance across revenue, gross margin, operating margin, and EBITDA.
🐂 Bull Case
The company has structurally shifted its margin profile. Non-GAAP Gross Margin hit 64.1%, shaking off the scrap rate and freight penalties of 2025. Operating leverage is firmly in place.
Positive RCT results for Type 2 non-insulin patients provide the required clinical evidence to pursue sweeping CMS/Medicare coverage, opening access to an estimated 12 million new potential users.
🐻 Bear Case
U.S. revenue growth decelerated to 11% YoY. While international markets are picking up the slack (+19%), the core domestic market is showing signs of maturation ahead of the CMS coverage unlock.
Despite current margin euphoria, management previously warned that the Q4 2026 activation of the new Ireland manufacturing facility will introduce significant fixed costs to COGS, temporarily pressuring margins at year-end.
⚖️ Verdict: 🟢
Bullish. The 13% revenue growth is solid, but the 590 basis point leap in operating margins and raised guidance prove Dexcom is executing flawlessly. The positive CONNECT trial results provide a clear runway for the next leg of structural growth.
Key Themes
Operating Leverage Reaches New Heights
Accelerating. Dexcom shattered expectations on profitability. Non-GAAP gross margin hit 64.1% (up from 60.1% a year ago), indicating that the manufacturing scrap issues and expedited freight costs from 2025 are entirely resolved. More impressively, strict OpEx control allowed the company to drop those gains straight to the bottom line, driving Non-GAAP operating margin to 25.1%—a massive 590 basis point YoY expansion.
CONNECT Trial Delivers the Holy Grail
Management announced positive results from the highly anticipated CONNECT randomized controlled trial. The study demonstrated statistically significant and clinically meaningful improvements in glucose control for Type 2 diabetes patients not on insulin. This specific data set is the exact catalyst management previously stated was necessary to secure broad CMS (Medicare) coverage, which represents approximately half of the non-insulin market.
U.S. Growth Shows Signs of Fatigue
Decelerating. A stark contradiction to the positive overall narrative is the core U.S. market. U.S. revenue grew just 11% YoY ($933.4M), down from 15% in Q2 2025 and 21% in Q3 2025. While International growth (+19%) is acting as a strong counterweight, the deceleration in the U.S. suggests that Dexcom desperately needs the CMS non-insulin unlock to re-accelerate domestic volume.
Stelo Evolution: AI Meets CGM
Dexcom initiated the launch of a 'fully reimagined' Stelo app experience. By integrating AI-driven insights and enhanced food logging capabilities directly into the interface, the company is pivoting Stelo from a simple biosensor into a comprehensive metabolic health and behavioral modification tool, widening its moat against pure-play software competitors in the cash-pay wellness market.
The Looming Q4 Margin Drag
While Dexcom raised full-year margin guidance, investors must remember the warning from prior quarters: the new Ireland manufacturing facility is scheduled to turn on in Q4 2026. Management previously stated this will cause a temporary decline in gross margins as fixed costs hit COGS against initially low production volumes. The current Q2 margin peak (64.1%) may represent a high-water mark for the year.
Geopolitical Macro Risks Still Plausible
Stable. In Q1 2026, the CFO explicitly held back from raising gross margin guidance due to a 50-100 basis point macro risk related to global fuel and resin prices stemming from geopolitical tensions. While Dexcom felt confident enough to raise the margin guide in Q2, these exogenous supply chain risks remain a monitoring point for a hardware-heavy company operating globally.
Other KPIs
Accelerating in mix. International revenue grew 19% on a reported basis (16% organic), vastly outperforming the 11% growth in the U.S. International now accounts for 28.6% of total revenue, up from 27.3% a year ago, validating management's long-term strategy to make the international business the primary growth engine.
Accelerating. Up a remarkable 38.5% YoY from $179.8 million in Q2 2025. Diluted EPS jumped to $0.64 from $0.45. This showcases the incredible operating leverage inherent in Dexcom's model once fixed R&D and SG&A costs are covered by scaled volume.
Stable. Total cash, cash equivalents, and marketable securities provide immense strategic flexibility. With the revolving credit facility remaining undrawn, Dexcom is heavily armed to defend market share or aggressively pursue tuck-in M&A.
Guidance
Accelerating vs prior guide. Management raised the midpoint, implying 11-13% YoY growth. While this represents a deceleration from the 16% growth seen in FY25, it confirms the business is tracking slightly ahead of the more conservative expectations set at the start of the year.
Accelerating. Raised from the previous range of 63-64%. Hitting the absolute top of the previous range for the full year suggests that manufacturing yields (particularly on the G7 15-day product) and global freight costs are performing better than the company's internal base-case models.
Accelerating. Raised from 23.0-23.5%. This is a massive upgrade and confirms that the staggering 25.1% margin delivered in Q2 was not entirely a one-off timing anomaly, but a structural shift in the company's profitability profile.
Accelerating. Raised from 31.0-31.5%. Consistently dropping operating efficiencies down to the EBITDA line demonstrates disciplined capital allocation and cost control across the enterprise.
Key Questions
CMS Submission Timeline
With the CONNECT trial yielding positive results, what is the exact regulatory and administrative timeline for submitting this data to CMS, and when is the earliest realistic effective date for broad Type 2 non-insulin Medicare coverage?
U.S. Re-acceleration Drivers
U.S. revenue growth stabilized at 11%. Prior to any CMS coverage unlock, what are the specific commercial levers (new product iterations, pricing, PCP sales force execution) that can push domestic growth back into the mid-to-high teens?
Ireland Facility Margin Impact
Given the raise to ~64% full-year gross margin guidance, has the anticipated margin dilution from turning on the new Ireland facility in Q4 been mitigated, or does this guidance simply reflect massive outperformance in Q2 and Q3 to offset the coming Q4 drag?